Skip to main content

29.10.2018 | Molecular Testing and Diagnostics (J Khoury, Section Editor) | Ausgabe 6/2018

Current Hematologic Malignancy Reports 6/2018

Chronic Myeloid Leukemia: Beyond BCR-ABL1

Current Hematologic Malignancy Reports > Ausgabe 6/2018
Ting Zhou, L. Jeffrey Medeiros, Shimin Hu
Wichtige Hinweise
This article is part of the Topical Collection on Molecular Testing and Diagnostics


Purpose of review

In this review, we emphasize up-to-date practical cytogenetic and molecular aspects of chronic myeloid leukemia (CML) and summarize current knowledge on tyrosine kinase inhibitor (TKI) resistance and treatment response monitoring of CML.

Recent findings

The introduction of TKIs has changed the natural course of CML and markedly improved patient survival. Over the past decades, many research efforts were devoted to elucidating the leukemogenic mechanisms of BCR-ABL1 and developing novel TKIs. More recent studies have attempted to answer new questions that have emerged in the TKI era, such as the cytogenetic and molecular bases of treatment failure and disease progression, the clinical impact of genetic aberrations in Philadelphia chromosome (Ph)-positive and Ph-negative cells, and the biological significance of Ph secondarily acquired during therapy of other hematological neoplasms.


Recent progresses in the understanding of the cytogenetic and molecular mechanisms underlying therapeutic failure and disease progression have improved the risk stratification of CML and will be helpful in the design of novel therapeutic strategies.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf

Jetzt e.Med zum Sonderpreis bestellen!

Sichern Sie sich jetzt Ihr e.Med-Abo und sparen Sie 50 %!

Weitere Produktempfehlungen anzeigen
Über diesen Artikel

Weitere Artikel der Ausgabe 6/2018

Current Hematologic Malignancy Reports 6/2018 Zur Ausgabe

Molecular Testing and Diagnostics (J Khoury, Section Editor)

Blastic Plasmacytoid Dendritic Cell Neoplasm

Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Social Media and Hematopoietic Cell Transplantation: a Review of Online Resources and Communities

Molecular Testing and Diagnostics (J Khoury, Section Editor)

Recent Updates on Chronic Myelomonocytic Leukemia

T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)

Breast Implant-Associated Anaplastic Large Cell Lymphoma

  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.